H2-Receptor Antagonist — Drug Intelligence | 4 EU Trials

Filter these 4 trials by condition, phase, country and more.

4 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

9 Countries

Phase III

Phase I/II

Phase I (FiH)

Phase III: 1 Phase I/II: 2 Phase I (FiH): 1

Oversight events:

2 serious breaches 2 temporary halts 2 unexpected events across 3 trials

Indications tested

4 total

Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting

2023-509306-29-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting

2023-509307-33-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009) Recruiting

2023-504910-31-00 Phase III 5 countries Merck Sharp & Dohme LLC
A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended

2023-506387-14-00 Phase I (FiH) 5 countries Merck Sharp & Dohme LLC

Showing 1–4 of 4 trials